I-Mab (NASDAQ:ARQT) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of I-Mab (NASDAQ:ARQT) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company’s product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California. “

Separately, Cantor Fitzgerald reissued a buy rating and issued a $50.00 price objective on shares of I-Mab in a report on Friday, March 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. I-Mab has a consensus rating of Hold and a consensus target price of $41.00.

I-Mab stock opened at $29.09 on Wednesday. The company has a 50-day simple moving average of $30.98. I-Mab has a one year low of $17.10 and a one year high of $40.88.

I-Mab (NASDAQ:ARQT) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.23). As a group, equities research analysts predict that I-Mab will post -3.39 EPS for the current year.

I-Mab Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

See Also: Hedge Funds

Get a free copy of the Zacks research report on I-Mab (ARQT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.